{
    "id": 5035,
    "date": "2026-06-15T10:48:44",
    "date_gmt": "2026-06-15T08:48:44",
    "guid": {
        "rendered": "https:\/\/www.phinc-group.com\/?p=5035"
    },
    "modified": "2026-06-26T16:56:15",
    "modified_gmt": "2026-06-26T14:56:15",
    "slug": "dose-optimization-in-oncology",
    "status": "publish",
    "type": "post",
    "link": "https:\/\/www.phinc-group.com\/fr\/dose-optimization-in-oncology\/",
    "title": {
        "rendered": "Optimisation\u00a0de la dose\u00a0en\u00a0oncologie\u00a0: un\u00a0d\u00e9fi\u00a0cach\u00e9\u00a0du MIDD \u00e0\u00a0l’\u00e8re\u00a0du\u00a0projet\u00a0Optimus"
    },
    "content": {
        "rendered": "<div data-elementor-type=\"wp-post\" data-elementor-id=\"5035\" class=\"elementor elementor-5035\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-87085f5 e-con-full e-flex e-con e-parent\" data-id=\"87085f5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-36c0dfc elementor-widget elementor-widget-html\" data-id=\"36c0dfc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<!doctype html>\r\n<html lang=\"fr\">\r\n<head>\r\n  <meta charset=\"utf-8\" \/>\r\n  <meta name=\"viewport\" content=\"width=device-width, initial-scale=1\" \/>\r\n  <title>Optimisation de la dose en oncologie : le d\u00e9fi cach\u00e9 du MIDD \u00e0 l'\u00e8re du projet Optimus \u2014 PhinC Group<\/title>\r\n  <style>\r\n    @import url('https:\/\/fonts.googleapis.com\/css2?family=Cormorant+Garamond:ital,wght@0,300;0,400;1,300;1,400&family=Poppins:wght@200;300;400;600;700&display=swap');\r\n\r\n    :root {\r\n      --phinc-blue: #00005f;\r\n      --phinc-pink: #d94b9f;\r\n      --ink: #0F172A;\r\n      --muted: #475569;\r\n      --line: #E6EAF2;\r\n      --bg: #F7F9FC;\r\n      --card: #FFFFFF;\r\n      --radius: 18px;\r\n      --shadow: 0 10px 30px rgba(15, 23, 42, .08);\r\n      --max: 860px;\r\n      --max-wide: 1100px;\r\n    }\r\n\r\n    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }\r\n\r\n    body {\r\n      font-family: 'Poppins', sans-serif;\r\n      color: var(--ink);\r\n      background: #fff;\r\n      line-height: 1.65;\r\n    }\r\n\r\n    \/* \u2500\u2500 HERO \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-hero {\r\n      background:\r\n        radial-gradient(1100px 500px at 95% 0%, rgba(217,75,159,.13), transparent 55%),\r\n        radial-gradient(800px 400px at 5% 20%, rgba(0,0,95,.12), transparent 50%),\r\n        linear-gradient(180deg, #ffffff 0%, var(--bg) 100%);\r\n      border-bottom: 1px solid var(--line);\r\n      padding: 80px 20px 0;\r\n    }\r\n\r\n    .opt-hero-inner {\r\n      max-width: var(--max-wide);\r\n      margin: 0 auto;\r\n    }\r\n\r\n    .opt-eyebrow {\r\n      display: inline-flex;\r\n      align-items: center;\r\n      gap: 10px;\r\n      padding: 7px 14px;\r\n      border: 1px solid var(--line);\r\n      border-radius: 999px;\r\n      font-size: 12px;\r\n      font-weight: 400;\r\n      color: var(--muted);\r\n      background: #fff;\r\n      margin-bottom: 22px;\r\n      letter-spacing: .04em;\r\n      text-transform: uppercase;\r\n    }\r\n\r\n    .opt-eyebrow-dot {\r\n      width: 8px; height: 8px;\r\n      border-radius: 999px;\r\n      background: linear-gradient(135deg, var(--phinc-pink), var(--phinc-blue));\r\n      flex: 0 0 auto;\r\n    }\r\n\r\n    .opt-hero h1 {\r\n      font-family: 'Cormorant Garamond', serif;\r\n      font-size: 50px;\r\n      font-weight: 300;\r\n      line-height: 1.15;\r\n      letter-spacing: -.01em;\r\n      max-width: 820px;\r\n      margin-bottom: 18px;\r\n    }\r\n\r\n    .opt-hero h1 span {\r\n      color: var(--phinc-pink);\r\n    }\r\n\r\n    .opt-hero-subtitle {\r\n      font-size: 18px;\r\n      font-weight: 200;\r\n      color: var(--muted);\r\n      line-height: 1.6;\r\n      max-width: 640px;\r\n      margin-bottom: 36px;\r\n    }\r\n\r\n    .opt-meta {\r\n      display: flex;\r\n      align-items: center;\r\n      gap: 12px;\r\n      flex-wrap: wrap;\r\n      margin-bottom: 36px;\r\n    }\r\n\r\n    .opt-meta-pill {\r\n      font-size: 12px;\r\n      padding: 6px 12px;\r\n      border: 1px solid var(--line);\r\n      border-radius: 999px;\r\n      color: var(--muted);\r\n      background: #fff;\r\n    }\r\n\r\n    \/* \u2500\u2500 HERO BANNER IMAGE \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-hero-banner {\r\n      width: 100%;\r\n      aspect-ratio: 16\/6;\r\n      border-radius: var(--radius) var(--radius) 0 0;\r\n      border: 1px solid var(--line);\r\n      border-bottom: none;\r\n      background: var(--bg);\r\n      background-image: url('https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/Image-1-\u2014-Banniere-hero-oncology-research-ratio-166-large.png');\r\n      background-size: cover;\r\n      background-position: center;\r\n      box-shadow: var(--shadow);\r\n    }\r\n\r\n    \/* \u2500\u2500 ARTICLE BODY \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-body {\r\n      max-width: var(--max);\r\n      margin: 0 auto;\r\n      padding: 60px 20px 64px;\r\n    }\r\n\r\n    \/* \u2500\u2500 INTRO \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-intro {\r\n      font-family: 'Cormorant Garamond', serif;\r\n      font-size: 26px;\r\n      font-weight: 300;\r\n      line-height: 1.5;\r\n      color: var(--ink);\r\n      margin-bottom: 48px;\r\n    }\r\n\r\n    \/* \u2500\u2500 SECTION TITLES \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-kicker {\r\n      font-size: 11px;\r\n      font-weight: 700;\r\n      letter-spacing: .18em;\r\n      text-transform: uppercase;\r\n      color: var(--phinc-pink);\r\n      margin-bottom: 8px;\r\n    }\r\n\r\n    .opt-section-title {\r\n      font-family: 'Cormorant Garamond', serif;\r\n      font-size: 36px;\r\n      font-weight: 300;\r\n      line-height: 1.15;\r\n      letter-spacing: -.01em;\r\n      margin-bottom: 18px;\r\n      color: var(--ink);\r\n    }\r\n\r\n    .opt-section-title span { color: var(--phinc-pink); }\r\n\r\n    \/* \u2500\u2500 BODY TEXT \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-p {\r\n      font-size: 16px;\r\n      font-weight: 300;\r\n      color: var(--muted);\r\n      line-height: 1.75;\r\n      margin-bottom: 20px;\r\n    }\r\n\r\n    .opt-p strong { font-weight: 600; color: var(--ink); }\r\n\r\n    \/* \u2500\u2500 PARADIGM SHIFT (DMT -> DBO) \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-shift {\r\n      display: grid;\r\n      grid-template-columns: 1fr auto 1fr;\r\n      gap: 20px;\r\n      align-items: center;\r\n      margin: 36px 0;\r\n    }\r\n\r\n    .opt-shift-card {\r\n      border: 1px solid var(--line);\r\n      border-radius: var(--radius);\r\n      padding: 28px 22px;\r\n      text-align: center;\r\n    }\r\n\r\n    .opt-shift-card.old {\r\n      background: var(--bg);\r\n      border-left: 3px solid #CBD5E1;\r\n    }\r\n\r\n    .opt-shift-card.new {\r\n      background: linear-gradient(135deg, rgba(0,0,95,.05), rgba(217,75,159,.08));\r\n      border-left: 3px solid var(--phinc-pink);\r\n    }\r\n\r\n    .opt-shift-label {\r\n      font-size: 11px;\r\n      font-weight: 700;\r\n      letter-spacing: .14em;\r\n      text-transform: uppercase;\r\n      margin-bottom: 10px;\r\n    }\r\n\r\n    .opt-shift-card.old .opt-shift-label { color: #94A3B8; }\r\n    .opt-shift-card.new .opt-shift-label { color: var(--phinc-pink); }\r\n\r\n    .opt-shift-acronym {\r\n      font-family: 'Cormorant Garamond', serif;\r\n      font-size: 42px;\r\n      font-weight: 400;\r\n      color: var(--ink);\r\n      margin-bottom: 8px;\r\n      line-height: 1;\r\n    }\r\n\r\n    .opt-shift-full {\r\n      font-size: 13px;\r\n      font-weight: 300;\r\n      color: var(--muted);\r\n      line-height: 1.4;\r\n    }\r\n\r\n    .opt-shift-arrow {\r\n      font-size: 28px;\r\n      color: var(--phinc-pink);\r\n      font-weight: 300;\r\n    }\r\n\r\n    @media (max-width: 640px) {\r\n      .opt-shift { grid-template-columns: 1fr; }\r\n      .opt-shift-arrow { transform: rotate(90deg); justify-self: center; }\r\n    }\r\n\r\n    \/* \u2500\u2500 HIGHLIGHT BOX (key message) \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-highlight {\r\n      background: linear-gradient(135deg, rgba(217,75,159,.06), rgba(0,0,95,.05));\r\n      border: 1px solid var(--line);\r\n      border-radius: var(--radius);\r\n      padding: 28px 32px;\r\n      margin: 36px 0;\r\n      border-left: 4px solid var(--phinc-pink);\r\n    }\r\n\r\n    .opt-highlight p {\r\n      font-family: 'Cormorant Garamond', serif;\r\n      font-size: 21px;\r\n      font-weight: 400;\r\n      line-height: 1.5;\r\n      color: var(--ink);\r\n    }\r\n\r\n    \/* \u2500\u2500 COMPLEXITY LIST (icon rows) \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-factor-list {\r\n      display: grid;\r\n      gap: 10px;\r\n      margin: 28px 0 36px;\r\n    }\r\n\r\n    .opt-factor {\r\n      display: flex;\r\n      align-items: flex-start;\r\n      gap: 14px;\r\n      padding: 16px 18px;\r\n      border: 1px solid var(--line);\r\n      border-radius: 12px;\r\n      background: var(--card);\r\n    }\r\n\r\n    .opt-factor-num {\r\n      font-family: 'Cormorant Garamond', serif;\r\n      font-size: 22px;\r\n      font-weight: 400;\r\n      color: var(--phinc-pink);\r\n      line-height: 1.3;\r\n      flex: 0 0 auto;\r\n      min-width: 28px;\r\n    }\r\n\r\n    .opt-factor p {\r\n      font-size: 14px;\r\n      font-weight: 300;\r\n      color: var(--muted);\r\n      line-height: 1.6;\r\n    }\r\n\r\n    .opt-factor strong {\r\n      font-weight: 600;\r\n      color: var(--ink);\r\n    }\r\n\r\n    \/* \u2500\u2500 IMAGE PLACEHOLDER \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-image-placeholder {\r\n      width: 100%;\r\n      aspect-ratio: 16\/8;\r\n      border-radius: var(--radius);\r\n      border: 1px solid var(--line);\r\n      background: var(--bg);\r\n      overflow: hidden;\r\n      margin: 40px 0;\r\n      background-size: cover;\r\n      background-position: center;\r\n      display: flex;\r\n      align-items: center;\r\n      justify-content: center;\r\n    }\r\n\r\n    .opt-image-placeholder.tall { aspect-ratio: 4\/3; }\r\n    .opt-image-placeholder.short { aspect-ratio: 21\/7; }\r\n\r\n    .opt-image-placeholder .ph-label {\r\n      font-size: 13px;\r\n      font-weight: 300;\r\n      color: var(--muted);\r\n      opacity: .55;\r\n      text-align: center;\r\n      padding: 20px;\r\n      pointer-events: none;\r\n    }\r\n\r\n    \/* \u2500\u2500 DOSE-RESPONSE CHART (SVG) \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-chart {\r\n      border: 1px solid var(--line);\r\n      border-radius: var(--radius);\r\n      background: var(--card);\r\n      padding: 28px 28px 24px;\r\n      margin: 40px 0;\r\n      box-shadow: 0 6px 20px rgba(15,23,42,.05);\r\n    }\r\n\r\n    .opt-chart svg {\r\n      width: 100%;\r\n      height: auto;\r\n      display: block;\r\n    }\r\n\r\n    .opt-chart-caption {\r\n      font-size: 13px;\r\n      font-weight: 300;\r\n      color: var(--muted);\r\n      line-height: 1.6;\r\n      margin-top: 18px;\r\n      padding-top: 16px;\r\n      border-top: 1px solid var(--line);\r\n    }\r\n\r\n    .opt-chart-caption strong {\r\n      font-weight: 600;\r\n      color: var(--ink);\r\n    }\r\n\r\n    \/* \u2500\u2500 OBO ZONE (target zone visual) \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-obo {\r\n      border: 1px solid var(--line);\r\n      border-radius: var(--radius);\r\n      background: var(--card);\r\n      padding: 32px;\r\n      margin: 36px 0;\r\n    }\r\n\r\n    .opt-obo h3 {\r\n      font-family: 'Cormorant Garamond', serif;\r\n      font-size: 26px;\r\n      font-weight: 300;\r\n      margin-bottom: 18px;\r\n    }\r\n\r\n    .opt-obo h3 span { color: var(--phinc-pink); }\r\n\r\n    .opt-obo-criteria {\r\n      display: grid;\r\n      grid-template-columns: repeat(2, 1fr);\r\n      gap: 12px;\r\n      margin-top: 18px;\r\n    }\r\n\r\n    .opt-obo-item {\r\n      display: flex;\r\n      align-items: flex-start;\r\n      gap: 10px;\r\n      font-size: 14px;\r\n      font-weight: 300;\r\n      color: var(--muted);\r\n      line-height: 1.5;\r\n    }\r\n\r\n    .opt-obo-check {\r\n      width: 18px; height: 18px;\r\n      border-radius: 6px;\r\n      background: linear-gradient(135deg, var(--phinc-blue), var(--phinc-pink));\r\n      flex: 0 0 auto;\r\n      margin-top: 2px;\r\n    }\r\n\r\n    @media (max-width: 640px) {\r\n      .opt-obo-criteria { grid-template-columns: 1fr; }\r\n    }\r\n\r\n    \/* \u2500\u2500 MIDD TOOLBOX TAGS \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-toolbox {\r\n      display: flex;\r\n      flex-wrap: wrap;\r\n      gap: 10px;\r\n      margin: 24px 0 36px;\r\n    }\r\n\r\n    .opt-tool-tag {\r\n      font-size: 13px;\r\n      font-weight: 400;\r\n      padding: 10px 16px;\r\n      border: 1px solid var(--line);\r\n      border-radius: 999px;\r\n      color: var(--ink);\r\n      background: var(--bg);\r\n      text-decoration: none;\r\n      transition: background .12s ease, color .12s ease, border-color .12s ease;\r\n    }\r\n\r\n    a.opt-tool-tag:hover {\r\n      background: var(--phinc-pink);\r\n      color: #fff;\r\n      border-color: var(--phinc-pink);\r\n    }\r\n\r\n    \/* \u2500\u2500 REGULATORY CALLOUT \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-reg-callout {\r\n      border: 1px solid var(--line);\r\n      border-radius: var(--radius);\r\n      padding: 28px 32px;\r\n      margin: 36px 0;\r\n      display: flex;\r\n      gap: 20px;\r\n      align-items: flex-start;\r\n      background: var(--bg);\r\n    }\r\n\r\n    .opt-reg-icon {\r\n      width: 44px; height: 44px;\r\n      border-radius: 12px;\r\n      background: linear-gradient(135deg, var(--phinc-blue), var(--phinc-pink));\r\n      display: flex; align-items: center; justify-content: center;\r\n      font-size: 20px;\r\n      flex: 0 0 auto;\r\n      color: #fff;\r\n    }\r\n\r\n    .opt-reg-callout h4 {\r\n      font-size: 16px;\r\n      font-weight: 600;\r\n      margin-bottom: 6px;\r\n    }\r\n\r\n    .opt-reg-callout p {\r\n      font-size: 14px;\r\n      font-weight: 300;\r\n      color: var(--muted);\r\n      line-height: 1.6;\r\n    }\r\n\r\n    .opt-reg-callout a {\r\n      color: var(--phinc-pink);\r\n      font-weight: 600;\r\n      text-decoration: none;\r\n      border-bottom: 1px solid rgba(217,75,159,.35);\r\n    }\r\n\r\n    .opt-reg-callout a:hover {\r\n      border-bottom-color: var(--phinc-pink);\r\n    }\r\n\r\n    \/* \u2500\u2500 CLOSING CTA \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-cta-block {\r\n      background: linear-gradient(135deg, var(--phinc-blue) 0%, #00008a 55%, #3d0050 100%);\r\n      border-radius: var(--radius);\r\n      padding: 52px 48px;\r\n      text-align: center;\r\n      margin-top: 56px;\r\n      position: relative;\r\n      overflow: hidden;\r\n    }\r\n\r\n    .opt-cta-block::before {\r\n      content: '';\r\n      position: absolute;\r\n      inset: 0;\r\n      background: radial-gradient(600px 400px at 80% 120%, rgba(217,75,159,.3), transparent 60%);\r\n      pointer-events: none;\r\n    }\r\n\r\n    .opt-cta-block h2 {\r\n      font-family: 'Cormorant Garamond', serif;\r\n      font-size: 40px;\r\n      font-weight: 300;\r\n      color: #fff;\r\n      margin-bottom: 14px;\r\n      position: relative;\r\n    }\r\n\r\n    .opt-cta-block h2 span { color: #f9b8e4; }\r\n\r\n    .opt-cta-block p {\r\n      font-size: 16px;\r\n      font-weight: 300;\r\n      color: rgba(255,255,255,.7);\r\n      max-width: 540px;\r\n      margin: 0 auto 30px;\r\n      line-height: 1.6;\r\n      position: relative;\r\n    }\r\n\r\n    .opt-btn {\r\n      display: inline-flex;\r\n      align-items: center;\r\n      gap: 10px;\r\n      padding: 15px 28px;\r\n      border-radius: 12px;\r\n      text-decoration: none;\r\n      font-weight: 600;\r\n      font-size: 15px;\r\n      position: relative;\r\n      cursor: pointer;\r\n      transition: transform .12s ease, box-shadow .12s ease;\r\n    }\r\n\r\n    .opt-btn:hover { transform: translateY(-2px); }\r\n\r\n    .opt-btn.primary {\r\n      background: var(--phinc-pink);\r\n      color: #fff;\r\n      border: none;\r\n      box-shadow: 0 8px 24px rgba(217,75,159,.4);\r\n    }\r\n\r\n    .opt-btn.primary:hover { box-shadow: 0 12px 32px rgba(217,75,159,.5); }\r\n\r\n    .opt-btn.ghost {\r\n      background: rgba(255,255,255,.12);\r\n      color: #fff;\r\n      border: 1px solid rgba(255,255,255,.25);\r\n      backdrop-filter: blur(4px);\r\n    }\r\n\r\n    .opt-cta-actions {\r\n      display: flex;\r\n      justify-content: center;\r\n      gap: 14px;\r\n      flex-wrap: wrap;\r\n    }\r\n\r\n    \/* \u2500\u2500 DIVIDER \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    .opt-divider {\r\n      height: 1px;\r\n      background: var(--line);\r\n      margin: 48px 0;\r\n    }\r\n\r\n    \/* \u2500\u2500 RESPONSIVE \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\r\n    @media (max-width: 780px) {\r\n      .opt-hero h1 { font-size: 36px; }\r\n      .opt-hero-banner { aspect-ratio: 4\/3; }\r\n      .opt-section-title { font-size: 28px; }\r\n      .opt-cta-block { padding: 36px 24px; }\r\n      .opt-cta-block h2 { font-size: 30px; }\r\n    }\r\n  <\/style>\r\n\r\n  <!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\r\n       HERO\r\n  \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\r\n  <header class=\"opt-hero\">\r\n    <div class=\"opt-hero-inner\">\r\n      <div class=\"opt-eyebrow\">\r\n        <span class=\"opt-eyebrow-dot\"><\/span>\r\n        Oncologie \u00b7 MIDD \u00b7 Projet Optimus\r\n      <\/div>\r\n      <h1>Optimisation de la dose en oncologie : <span>le d\u00e9fi cach\u00e9<\/span> du MIDD \u00e0 l'\u00e8re du projet Optimus<\/h1>\r\n      <p class=\"opt-hero-subtitle\">\r\n        La dose maximale tol\u00e9r\u00e9e a longtemps guid\u00e9 l'oncologie. Avec les th\u00e9rapies modernes, ce paradigme\r\n        ne suffit plus \u2014 et la FDA en a fait une priorit\u00e9 r\u00e9glementaire.\r\n      <\/p>\r\n      <div class=\"opt-meta\">\r\n        <span class=\"opt-meta-pill\">Oncologie<\/span>\r\n        <span class=\"opt-meta-pill\">Projet Optimus \u00b7 FDA<\/span>\r\n        <span class=\"opt-meta-pill\">PK\/PD \u00b7 QSP \u00b7 PBPK<\/span>\r\n      <\/div>\r\n\r\n      <div class=\"opt-hero-banner\" aria-label=\"Image banni\u00e8re oncologie\"><\/div>\r\n    <\/div>\r\n  <\/header>\r\n\r\n  <!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\r\n       BODY\r\n  \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\r\n  <article class=\"opt-body\">\r\n\r\n    <!-- Intro -->\r\n    <p class=\"opt-intro\">\r\n      Pendant des d\u00e9cennies, le d\u00e9veloppement des m\u00e9dicaments en oncologie a suivi un principe simple :\r\n      administrer la dose la plus \u00e9lev\u00e9e que les patients pouvaient tol\u00e9rer. Avec les th\u00e9rapies\r\n      d'aujourd'hui, ce principe ne tient plus.\r\n    <\/p>\r\n\r\n    <!-- \u2500\u2500 PARTIE 1 : LE PARADIGME QUI CHANGE \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 -->\r\n    <div class=\"opt-kicker\">Un paradigme d\u00e9pass\u00e9<\/div>\r\n    <h2 class=\"opt-section-title\">La dose la plus <span>tol\u00e9r\u00e9e<\/span> n'est plus la dose <span>optimale<\/span><\/h2>\r\n\r\n    <p class=\"opt-p\">\r\n      L'approche de la \u00ab dose maximale tol\u00e9r\u00e9e \u00bb (DMT) \u00e9tait bien adapt\u00e9e aux chimioth\u00e9rapies traditionnelles,\r\n      o\u00f9 une exposition accrue conduisait g\u00e9n\u00e9ralement \u00e0 une destruction plus importante des cellules\r\n      tumorales. Les th\u00e9rapies oncologiques d'aujourd'hui sont fondamentalement diff\u00e9rentes.\r\n    <\/p>\r\n\r\n    <p class=\"opt-p\">\r\n      Les th\u00e9rapies cibl\u00e9es, les conjugu\u00e9s anticorps-m\u00e9dicaments (ADC), les anticorps bisp\u00e9cifiques et\r\n      les immunoth\u00e9rapies agissent par des m\u00e9canismes biologiques hautement sp\u00e9cifiques. Dans de nombreux\r\n      cas, <strong>l'efficacit\u00e9 atteint un plateau<\/strong> une fois qu'un engagement suffisant de la cible\r\n      est obtenu, tandis que <strong>la toxicit\u00e9 continue d'augmenter<\/strong> avec la dose.\r\n    <\/p>\r\n\r\n    <div class=\"opt-shift\">\r\n      <div class=\"opt-shift-card old\">\r\n        <div class=\"opt-shift-label\">Paradigme historique<\/div>\r\n        <div class=\"opt-shift-acronym\">DMT<\/div>\r\n        <div class=\"opt-shift-full\">Dose Maximale Tol\u00e9r\u00e9e \u2014 administrer la dose la plus \u00e9lev\u00e9e tol\u00e9rable par les patients<\/div>\r\n      <\/div>\r\n      <div class=\"opt-shift-arrow\">\u2192<\/div>\r\n      <div class=\"opt-shift-card new\">\r\n        <div class=\"opt-shift-label\">Nouvelle attente r\u00e9glementaire<\/div>\r\n        <div class=\"opt-shift-acronym\">DBO<\/div>\r\n        <div class=\"opt-shift-full\">Dose Biologique Optimale \u2014 identifier le meilleur \u00e9quilibre b\u00e9n\u00e9fice-risque<\/div>\r\n      <\/div>\r\n    <\/div>\r\n\r\n    <p class=\"opt-p\">\r\n      Ce changement a transform\u00e9 l'optimisation de la dose en l'un des d\u00e9fis les plus importants \u2014 et\r\n      souvent sous-estim\u00e9s \u2014 du d\u00e9veloppement en oncologie.\r\n    <\/p>\r\n\r\n    <div class=\"opt-divider\"><\/div>\r\n\r\n    <!-- \u2500\u2500 PARTIE 2 : PROJET OPTIMUS \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 -->\r\n    <div class=\"opt-kicker\">Contexte r\u00e9glementaire<\/div>\r\n    <h2 class=\"opt-section-title\">Projet <span>Optimus<\/span> : une nouvelle attente de la FDA<\/h2>\r\n\r\n    <p class=\"opt-p\">\r\n      Reconnaissant les limites du paradigme traditionnel de la DMT, la FDA a lanc\u00e9 le\r\n      <strong><a href=\"https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus\" target=\"_blank\" rel=\"noopener\" style=\"color: var(--phinc-pink); text-decoration: none; border-bottom: 1px solid rgba(217,75,159,.35);\">projet Optimus<\/a><\/strong>\r\n      pour am\u00e9liorer la s\u00e9lection des doses en oncologie et encourager une compr\u00e9hension plus globale de\r\n      la relation entre dose, exposition, efficacit\u00e9 et s\u00e9curit\u00e9.\r\n    <\/p>\r\n\r\n    <p class=\"opt-p\">\r\n      L'initiative met les promoteurs au d\u00e9fi d'aller au-del\u00e0 de l'identification de la dose maximale\r\n      tol\u00e9rable pour d\u00e9terminer la dose qui offre le <strong>meilleur profil b\u00e9n\u00e9fice-risque global<\/strong>\r\n      pour les patients.\r\n    <\/p>\r\n\r\n    <div class=\"opt-highlight\">\r\n      <p>La dose optimale n'est pas n\u00e9cessairement la dose maximale tol\u00e9r\u00e9e.<\/p>\r\n    <\/div>\r\n\r\n    <div class=\"opt-chart\" aria-label=\"Graphique : courbe dose-r\u00e9ponse et fen\u00eatre th\u00e9rapeutique\">\r\n      <svg viewbox=\"0 0 900 420\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" role=\"img\" aria-labelledby=\"optChartTitle optChartDesc\">\r\n        <title id=\"optChartTitle\">Dose-response curve in oncology<\/title>\r\n        <desc id=\"optChartDesc\">Efficacy reaching a plateau and toxicity increasing with dose, highlighting the optimal therapeutic window (OBD).<\/desc>\r\n\r\n        <defs>\r\n          <lineargradient id=\"optZoneGrad\" x1=\"0\" y1=\"0\" x2=\"0\" y2=\"1\">\r\n            <stop offset=\"0%\" stop-color=\"#d94b9f\" stop-opacity=\"0.16\"\/>\r\n            <stop offset=\"100%\" stop-color=\"#00005f\" stop-opacity=\"0.08\"\/>\r\n          <\/lineargradient>\r\n          <lineargradient id=\"optEfficacyGrad\" x1=\"0\" y1=\"0\" x2=\"1\" y2=\"0\">\r\n            <stop offset=\"0%\" stop-color=\"#00005f\"\/>\r\n            <stop offset=\"100%\" stop-color=\"#3a3aa8\"\/>\r\n          <\/lineargradient>\r\n          <lineargradient id=\"optToxicityGrad\" x1=\"0\" y1=\"0\" x2=\"1\" y2=\"0\">\r\n            <stop offset=\"0%\" stop-color=\"#f3a6cf\"\/>\r\n            <stop offset=\"100%\" stop-color=\"#d94b9f\"\/>\r\n          <\/lineargradient>\r\n        <\/defs>\r\n\r\n        <!-- Plot area background -->\r\n        <rect x=\"70\" y=\"30\" width=\"780\" height=\"320\" fill=\"#F7F9FC\" rx=\"14\"\/>\r\n\r\n        <!-- Therapeutic window (OBD zone) -->\r\n        <rect x=\"430\" y=\"30\" width=\"160\" height=\"320\" fill=\"url(#optZoneGrad)\"\/>\r\n        <line x1=\"430\" y1=\"30\" x2=\"430\" y2=\"350\" stroke=\"#d94b9f\" stroke-width=\"1.5\" stroke-dasharray=\"4 4\" opacity=\"0.6\"\/>\r\n        <line x1=\"590\" y1=\"30\" x2=\"590\" y2=\"350\" stroke=\"#d94b9f\" stroke-width=\"1.5\" stroke-dasharray=\"4 4\" opacity=\"0.6\"\/>\r\n\r\n        <!-- Axes -->\r\n        <line x1=\"70\" y1=\"350\" x2=\"850\" y2=\"350\" stroke=\"#475569\" stroke-width=\"1.5\"\/>\r\n        <line x1=\"70\" y1=\"30\" x2=\"70\" y2=\"350\" stroke=\"#475569\" stroke-width=\"1.5\"\/>\r\n\r\n        <!-- Toxicity curve: increasing, concave-up -->\r\n        <path d=\"M 70 340                 C 220 335, 350 320, 460 270                 C 580 215, 700 130, 850 60\"\r\n              fill=\"none\" stroke=\"url(#optToxicityGrad)\" stroke-width=\"4\" stroke-linecap=\"round\"\/>\r\n\r\n        <!-- Efficacy curve: rises then plateaus -->\r\n        <path d=\"M 70 345                 C 180 300, 280 130, 400 75                 C 520 45, 700 38, 850 35\"\r\n              fill=\"none\" stroke=\"url(#optEfficacyGrad)\" stroke-width=\"4\" stroke-linecap=\"round\"\/>\r\n\r\n        <!-- OBD marker -->\r\n        <circle cx=\"510\" cy=\"56\" r=\"6\" fill=\"#00005f\"\/>\r\n        <circle cx=\"510\" cy=\"190\" r=\"6\" fill=\"#d94b9f\"\/>\r\n\r\n        <!-- OBD zone label -->\r\n        <text x=\"510\" y=\"20\" text-anchor=\"middle\" font-family=\"Poppins, sans-serif\" font-size=\"13\" font-weight=\"600\" fill=\"#0F172A\">OBD Zone<\/text>\r\n\r\n        <!-- Curve labels -->\r\n        <text x=\"790\" y=\"28\" text-anchor=\"end\" font-family=\"Poppins, sans-serif\" font-size=\"13\" font-weight=\"600\" fill=\"#00005f\">Efficacy<\/text>\r\n        <text x=\"790\" y=\"78\" text-anchor=\"end\" font-family=\"Poppins, sans-serif\" font-size=\"13\" font-weight=\"600\" fill=\"#d94b9f\">Toxicity<\/text>\r\n\r\n        <!-- Axis labels -->\r\n        <text x=\"460\" y=\"395\" text-anchor=\"middle\" font-family=\"Poppins, sans-serif\" font-size=\"14\" font-weight=\"300\" fill=\"#475569\">Dose \/ Exposure<\/text>\r\n        <text x=\"30\" y=\"190\" text-anchor=\"middle\" font-family=\"Poppins, sans-serif\" font-size=\"14\" font-weight=\"300\" fill=\"#475569\" transform=\"rotate(-90 30 190)\">Response<\/text>\r\n\r\n        <!-- MTD marker (far right of axis) -->\r\n        <line x1=\"850\" y1=\"350\" x2=\"850\" y2=\"30\" stroke=\"#94A3B8\" stroke-width=\"1\" stroke-dasharray=\"2 3\"\/>\r\n        <text x=\"850\" y=\"370\" text-anchor=\"middle\" font-family=\"Poppins, sans-serif\" font-size=\"12\" font-weight=\"400\" fill=\"#94A3B8\">MTD<\/text>\r\n\r\n      <\/svg>\r\n      <p class=\"opt-chart-caption\">\r\n        L'efficacit\u00e9 atteint rapidement un plateau, tandis que la toxicit\u00e9 continue d'augmenter avec la dose.\r\n        La <strong>zone DBO<\/strong> (dose biologique optimale) se situe avant la DMT, l\u00e0 o\u00f9 le b\u00e9n\u00e9fice clinique\r\n        est maximal pour un niveau de toxicit\u00e9 encore g\u00e9rable.\r\n      <\/p>\r\n    <\/div>\r\n\r\n\r\n    <div class=\"opt-divider\"><\/div>\r\n\r\n    <!-- \u2500\u2500 PARTIE 3 : POURQUOI C'EST PLUS COMPLEXE \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 -->\r\n    <div class=\"opt-kicker\">Complexit\u00e9 biologique<\/div>\r\n    <h2 class=\"opt-section-title\">Pourquoi l'optimisation de la dose est plus complexe que jamais<\/h2>\r\n\r\n    <p class=\"opt-p\">\r\n      Les th\u00e9rapies modernes introduisent des complexit\u00e9s biologiques que les \u00e9tudes traditionnelles\r\n      d'escalade de dose ne parviennent souvent pas \u00e0 capturer :\r\n    <\/p>\r\n\r\n    <div class=\"opt-factor-list\">\r\n      <div class=\"opt-factor\">\r\n        <div class=\"opt-factor-num\">01<\/div>\r\n        <p><strong>Saturation des r\u00e9cepteurs<\/strong> et plateaux d'engagement de la cible<\/p>\r\n      <\/div>\r\n      <div class=\"opt-factor\">\r\n        <div class=\"opt-factor-num\">02<\/div>\r\n        <p><strong>Relations exposition-r\u00e9ponse non lin\u00e9aires<\/strong>, difficiles \u00e0 extrapoler par escalade classique<\/p>\r\n      <\/div>\r\n      <div class=\"opt-factor\">\r\n        <div class=\"opt-factor-num\">03<\/div>\r\n        <p><strong>Dynamique complexe du syst\u00e8me immunitaire<\/strong>, propre aux immunoth\u00e9rapies<\/p>\r\n      <\/div>\r\n      <div class=\"opt-factor\">\r\n        <div class=\"opt-factor-num\">04<\/div>\r\n        <p><strong>Toxicit\u00e9 retard\u00e9e et cumulative<\/strong>, qui n'appara\u00eet pas dans les premiers cycles<\/p>\r\n      <\/div>\r\n      <div class=\"opt-factor\">\r\n        <div class=\"opt-factor-num\">05<\/div>\r\n        <p><strong>\u00c9volution tumorale et m\u00e9canismes de r\u00e9sistance<\/strong> au fil du traitement<\/p>\r\n      <\/div>\r\n      <div class=\"opt-factor\">\r\n        <div class=\"opt-factor-num\">06<\/div>\r\n        <p><strong>Traitements au long cours<\/strong> n\u00e9cessitant une tol\u00e9rance durable<\/p>\r\n      <\/div>\r\n    <\/div>\r\n\r\n    <p class=\"opt-p\">\r\n      Ces facteurs rendent l'optimisation de la dose bien plus difficile que la simple identification\r\n      d'un seuil de toxicit\u00e9.\r\n    <\/p>\r\n\r\n    <div class=\"opt-divider\"><\/div>\r\n\r\n    <!-- \u2500\u2500 PARTIE 4 : LE R\u00d4LE DU MIDD \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 -->\r\n    <div class=\"opt-kicker\">La r\u00e9ponse<\/div>\r\n    <h2 class=\"opt-section-title\">Pourquoi le <span>MIDD<\/span> est au c\u0153ur du projet Optimus<\/h2>\r\n\r\n    <p class=\"opt-p\">\r\n      Le d\u00e9veloppement de m\u00e9dicaments inform\u00e9 par la mod\u00e9lisation (MIDD) fournit le cadre quantitatif\r\n      n\u00e9cessaire pour comprendre comment la dose, l'exposition, l'efficacit\u00e9, les biomarqueurs et la\r\n      s\u00e9curit\u00e9 interagissent tout au long du d\u00e9veloppement.\r\n    <\/p>\r\n\r\n    <p class=\"opt-p\">\r\n      En int\u00e9grant des donn\u00e9es pharmacocin\u00e9tiques (PK), pharmacodynamiques (PD), de biomarqueurs,\r\n      d'efficacit\u00e9 et de s\u00e9curit\u00e9, le MIDD permet aux promoteurs d'\u00e9valuer de multiples strat\u00e9gies de\r\n      dosage <strong>avant la r\u00e9alisation d'essais cliniques \u00e0 grande \u00e9chelle<\/strong>.\r\n    <\/p>\r\n\r\n    <div class=\"opt-image-placeholder tall\" aria-label=\"Image : \u00e9quipe scientifique mod\u00e9lisation oncologie\" style=\"background-image:url('https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/Image-3-\u2014-Equipe-scientifique-modelisation-oncologie-ratio-43.png');\"><\/div>\r\n\r\n    <div class=\"opt-shift\" style=\"margin-top:0;\">\r\n      <div class=\"opt-shift-card old\">\r\n        <div class=\"opt-shift-label\">Question traditionnelle<\/div>\r\n        <div class=\"opt-shift-full\" style=\"font-style:italic; font-size:15px; color:var(--ink);\">\r\n          \u00ab Quelle est la dose la plus \u00e9lev\u00e9e que les patients peuvent tol\u00e9rer ? \u00bb\r\n        <\/div>\r\n      <\/div>\r\n      <div class=\"opt-shift-arrow\">\u2192<\/div>\r\n      <div class=\"opt-shift-card new\">\r\n        <div class=\"opt-shift-label\">Question MIDD<\/div>\r\n        <div class=\"opt-shift-full\" style=\"font-style:italic; font-size:15px; color:var(--ink);\">\r\n          \u00ab Quelle dose offre l'\u00e9quilibre optimal entre efficacit\u00e9, s\u00e9curit\u00e9, tol\u00e9rance \u00e0 long terme et b\u00e9n\u00e9fice pour le patient ? \u00bb\r\n        <\/div>\r\n      <\/div>\r\n    <\/div>\r\n\r\n    <p class=\"opt-p\">\r\n      C'est l\u00e0 le changement fondamental que le projet Optimus cherche \u00e0 r\u00e9aliser.\r\n    <\/p>\r\n\r\n    <div class=\"opt-divider\"><\/div>\r\n\r\n    <!-- \u2500\u2500 PARTIE 5 : LA DBO \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 -->\r\n    <div class=\"opt-kicker\">L'objectif final<\/div>\r\n    <h2 class=\"opt-section-title\">De la dose maximale tol\u00e9r\u00e9e \u00e0 la <span>dose biologique optimale<\/span><\/h2>\r\n\r\n    <p class=\"opt-p\">\r\n      L'un des objectifs principaux du MIDD est d'identifier la <strong>dose biologique optimale (DBO)<\/strong>\r\n      \u2014 la plage d'exposition o\u00f9 plusieurs conditions sont r\u00e9unies simultan\u00e9ment.\r\n    <\/p>\r\n\r\n    <div class=\"opt-obo\">\r\n      <h3>La zone <span>DBO<\/span> : quatre conditions \u00e0 r\u00e9unir<\/h3>\r\n      <div class=\"opt-obo-criteria\">\r\n        <div class=\"opt-obo-item\">\r\n          <span class=\"opt-obo-check\"><\/span>\r\n          L'engagement de la cible est suffisant\r\n        <\/div>\r\n        <div class=\"opt-obo-item\">\r\n          <span class=\"opt-obo-check\"><\/span>\r\n          Le b\u00e9n\u00e9fice clinique approche son maximum\r\n        <\/div>\r\n        <div class=\"opt-obo-item\">\r\n          <span class=\"opt-obo-check\"><\/span>\r\n          Une exposition suppl\u00e9mentaire n'apporte qu'une efficacit\u00e9 incr\u00e9mentale limit\u00e9e\r\n        <\/div>\r\n        <div class=\"opt-obo-item\">\r\n          <span class=\"opt-obo-check\"><\/span>\r\n          La toxicit\u00e9 reste g\u00e9rable\r\n        <\/div>\r\n      <\/div>\r\n    <\/div>\r\n\r\n    <p class=\"opt-p\">\r\n      Pour appuyer la s\u00e9lection de la DBO, le MIDD mobilise un ensemble d'approches compl\u00e9mentaires :\r\n    <\/p>\r\n\r\n    <div class=\"opt-toolbox\">\r\n      <a class=\"opt-tool-tag\" href=\"\/fr\/approches\/exposure-response\/\">Analyses exposition-r\u00e9ponse<\/a>\r\n      <a class=\"opt-tool-tag\" href=\"\/fr\/approches\/popPK\/\">Mod\u00e9lisation PK de population<\/a>\r\n      <a class=\"opt-tool-tag\" href=\"\/fr\/approches\/pkpd\/\">Mod\u00e9lisation PK\/PD<\/a>\r\n      <a class=\"opt-tool-tag\" href=\"\/fr\/approches\/pbpk\/\">PBPK<\/a>\r\n      <a class=\"opt-tool-tag\" href=\"\/fr\/approches\/qsp\/\">QSP<\/a>\r\n      <a class=\"opt-tool-tag\" href=\"\/fr\/approches\/cts\/\">Simulations d'essais cliniques<\/a>\r\n      <span class=\"opt-tool-tag\">Pr\u00e9vision de s\u00e9curit\u00e9 \u00e0 long terme<\/span>\r\n      <span class=\"opt-tool-tag\">Optimisation des th\u00e9rapies combin\u00e9es<\/span>\r\n    <\/div>\r\n\r\n    <div class=\"opt-reg-callout\">\r\n      <div class=\"opt-reg-icon\">\ud83c\uddfa\ud83c\uddf8<\/div>\r\n      <div>\r\n        <h4>Une feuille de route align\u00e9e avec les attentes de la FDA<\/h4>\r\n        <p>\r\n          En structurant la strat\u00e9gie de d\u00e9veloppement autour de la DBO plut\u00f4t que de la DMT, les promoteurs\r\n          r\u00e9pondent directement aux exigences du\r\n          <a href=\"https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus\" target=\"_blank\" rel=\"noopener\">projet Optimus<\/a>\r\n          \u2014 et renforcent leur dialogue avec les autorit\u00e9s r\u00e9glementaires d\u00e8s les premi\u00e8res phases.\r\n        <\/p>\r\n      <\/div>\r\n    <\/div>\r\n\r\n    <!-- \u2500\u2500 CTA FINAL \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 -->\r\n    <div class=\"opt-cta-block\">\r\n      <h2>Optimiser votre <span>strat\u00e9gie de dose<\/span> en oncologie ?<\/h2>\r\n      <p>\r\n        Partagez le profil de votre mol\u00e9cule, son m\u00e9canisme d'action et votre stade de d\u00e9veloppement.\r\n        Nous vous proposons une approche MIDD align\u00e9e avec les attentes du projet Optimus.\r\n      <\/p>\r\n      <div class=\"opt-cta-actions\">\r\n        <a class=\"opt-btn primary\" href=\"\/fr\/contact\/\">Planifier un \u00e9change<\/a>\r\n        <a class=\"opt-btn ghost\" href=\"\/fr\/service\/midd\/\">D\u00e9couvrir notre offre MIDD<\/a>\r\n      <\/div>\r\n    <\/div>\r\n\r\n  <\/article>\r\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>",
        "protected": false
    },
    "excerpt": {
        "rendered": "<p>Pendant des d\u00e9cennies, l&rsquo;oncologie a suivi un principe simple : administrer la dose maximale tol\u00e9r\u00e9e. Avec les th\u00e9rapies modernes, ce paradigme ne tient plus \u2014 d\u00e9couvrez comment le MIDD r\u00e9pond aux nouvelles attentes du projet Optimus de la FDA.<\/p>",
        "protected": false
    },
    "author": 2,
    "featured_media": 5047,
    "comment_status": "closed",
    "ping_status": "closed",
    "sticky": false,
    "template": "elementor_header_footer",
    "format": "standard",
    "meta": {
        "_acf_changed": false,
        "footnotes": ""
    },
    "categories": [
        37,
        40
    ],
    "tags": [],
    "service-associe": [],
    "class_list": [
        "post-5035",
        "post",
        "type-post",
        "status-publish",
        "format-standard",
        "has-post-thumbnail",
        "hentry",
        "category-blog",
        "category-insights"
    ],
    "acf": [],
    "yoast_head": "<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Optimisation\u00a0de la dose\u00a0en\u00a0oncologie\u00a0: un\u00a0d\u00e9fi\u00a0cach\u00e9\u00a0du MIDD \u00e0\u00a0l&#039;\u00e8re\u00a0du\u00a0projet\u00a0Optimus - PhinC Group<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.phinc-group.com\/fr\/dose-optimization-in-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Optimisation\u00a0de la dose\u00a0en\u00a0oncologie\u00a0: un\u00a0d\u00e9fi\u00a0cach\u00e9\u00a0du MIDD \u00e0\u00a0l&#039;\u00e8re\u00a0du\u00a0projet\u00a0Optimus - PhinC Group\" \/>\n<meta property=\"og:description\" content=\"Pendant des d\u00e9cennies, l&#039;oncologie a suivi un principe simple : administrer la dose maximale tol\u00e9r\u00e9e. Avec les th\u00e9rapies modernes, ce paradigme ne tient plus \u2014 d\u00e9couvrez comment le MIDD r\u00e9pond aux nouvelles attentes du projet Optimus de la FDA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.phinc-group.com\/fr\/dose-optimization-in-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"PhinC Group\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T08:48:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T14:56:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/image-a-la-une-midd-challenge-oncology-optimus-project.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1514\" \/>\n\t<meta property=\"og:image:height\" content=\"1039\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mohamed Taourirt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mohamed Taourirt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/dose-optimization-in-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/dose-optimization-in-oncology\\\/\"},\"author\":{\"name\":\"Mohamed Taourirt\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\"},\"headline\":\"Optimisation\u00a0de la dose\u00a0en\u00a0oncologie\u00a0: un\u00a0d\u00e9fi\u00a0cach\u00e9\u00a0du MIDD \u00e0\u00a0l&rsquo;\u00e8re\u00a0du\u00a0projet\u00a0Optimus\",\"datePublished\":\"2026-06-15T08:48:44+00:00\",\"dateModified\":\"2026-06-26T14:56:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/dose-optimization-in-oncology\\\/\"},\"wordCount\":997,\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/dose-optimization-in-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/image-a-la-une-midd-challenge-oncology-optimus-project.png\",\"articleSection\":[\"Blog\",\"Insights\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/dose-optimization-in-oncology\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/dose-optimization-in-oncology\\\/\",\"name\":\"Optimisation\u00a0de la dose\u00a0en\u00a0oncologie\u00a0: un\u00a0d\u00e9fi\u00a0cach\u00e9\u00a0du MIDD \u00e0\u00a0l'\u00e8re\u00a0du\u00a0projet\u00a0Optimus - PhinC Group\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/dose-optimization-in-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/dose-optimization-in-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/image-a-la-une-midd-challenge-oncology-optimus-project.png\",\"datePublished\":\"2026-06-15T08:48:44+00:00\",\"dateModified\":\"2026-06-26T14:56:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/dose-optimization-in-oncology\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.phinc-group.com\\\/dose-optimization-in-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/dose-optimization-in-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/image-a-la-une-midd-challenge-oncology-optimus-project.png\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/image-a-la-une-midd-challenge-oncology-optimus-project.png\",\"width\":1514,\"height\":1039},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/dose-optimization-in-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.phinc-group.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Optimisation\u00a0de la dose\u00a0en\u00a0oncologie\u00a0: un\u00a0d\u00e9fi\u00a0cach\u00e9\u00a0du MIDD \u00e0\u00a0l&rsquo;\u00e8re\u00a0du\u00a0projet\u00a0Optimus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"name\":\"PhinC Group\",\"description\":\"Quantitative Pharmacology Solutions &amp; Modeling\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\",\"name\":\"PhinC Group\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"width\":600,\"height\":600,\"caption\":\"PhinC Group\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\",\"name\":\"Mohamed Taourirt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"caption\":\"Mohamed Taourirt\"},\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/author\\\/mtaourirt\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->",
    "yoast_head_json": {
        "title": "Optimisation\u00a0de la dose\u00a0en\u00a0oncologie\u00a0: un\u00a0d\u00e9fi\u00a0cach\u00e9\u00a0du MIDD \u00e0\u00a0l'\u00e8re\u00a0du\u00a0projet\u00a0Optimus - PhinC Group",
        "robots": {
            "index": "index",
            "follow": "follow",
            "max-snippet": "max-snippet:-1",
            "max-image-preview": "max-image-preview:large",
            "max-video-preview": "max-video-preview:-1"
        },
        "canonical": "https:\/\/www.phinc-group.com\/fr\/dose-optimization-in-oncology\/",
        "og_locale": "fr_FR",
        "og_type": "article",
        "og_title": "Optimisation\u00a0de la dose\u00a0en\u00a0oncologie\u00a0: un\u00a0d\u00e9fi\u00a0cach\u00e9\u00a0du MIDD \u00e0\u00a0l'\u00e8re\u00a0du\u00a0projet\u00a0Optimus - PhinC Group",
        "og_description": "Pendant des d\u00e9cennies, l'oncologie a suivi un principe simple : administrer la dose maximale tol\u00e9r\u00e9e. Avec les th\u00e9rapies modernes, ce paradigme ne tient plus \u2014 d\u00e9couvrez comment le MIDD r\u00e9pond aux nouvelles attentes du projet Optimus de la FDA.",
        "og_url": "https:\/\/www.phinc-group.com\/fr\/dose-optimization-in-oncology\/",
        "og_site_name": "PhinC Group",
        "article_published_time": "2026-06-15T08:48:44+00:00",
        "article_modified_time": "2026-06-26T14:56:15+00:00",
        "og_image": [
            {
                "width": 1514,
                "height": 1039,
                "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/image-a-la-une-midd-challenge-oncology-optimus-project.png",
                "type": "image\/png"
            }
        ],
        "author": "Mohamed Taourirt",
        "twitter_card": "summary_large_image",
        "twitter_misc": {
            "\u00c9crit par": "Mohamed Taourirt",
            "Dur\u00e9e de lecture estim\u00e9e": "5 minutes"
        },
        "schema": {
            "@context": "https:\/\/schema.org",
            "@graph": [
                {
                    "@type": "Article",
                    "@id": "https:\/\/www.phinc-group.com\/dose-optimization-in-oncology\/#article",
                    "isPartOf": {
                        "@id": "https:\/\/www.phinc-group.com\/dose-optimization-in-oncology\/"
                    },
                    "author": {
                        "name": "Mohamed Taourirt",
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a"
                    },
                    "headline": "Optimisation\u00a0de la dose\u00a0en\u00a0oncologie\u00a0: un\u00a0d\u00e9fi\u00a0cach\u00e9\u00a0du MIDD \u00e0\u00a0l&rsquo;\u00e8re\u00a0du\u00a0projet\u00a0Optimus",
                    "datePublished": "2026-06-15T08:48:44+00:00",
                    "dateModified": "2026-06-26T14:56:15+00:00",
                    "mainEntityOfPage": {
                        "@id": "https:\/\/www.phinc-group.com\/dose-optimization-in-oncology\/"
                    },
                    "wordCount": 997,
                    "publisher": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#organization"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/dose-optimization-in-oncology\/#primaryimage"
                    },
                    "thumbnailUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/image-a-la-une-midd-challenge-oncology-optimus-project.png",
                    "articleSection": [
                        "Blog",
                        "Insights"
                    ],
                    "inLanguage": "fr-FR"
                },
                {
                    "@type": "WebPage",
                    "@id": "https:\/\/www.phinc-group.com\/dose-optimization-in-oncology\/",
                    "url": "https:\/\/www.phinc-group.com\/dose-optimization-in-oncology\/",
                    "name": "Optimisation\u00a0de la dose\u00a0en\u00a0oncologie\u00a0: un\u00a0d\u00e9fi\u00a0cach\u00e9\u00a0du MIDD \u00e0\u00a0l'\u00e8re\u00a0du\u00a0projet\u00a0Optimus - PhinC Group",
                    "isPartOf": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#website"
                    },
                    "primaryImageOfPage": {
                        "@id": "https:\/\/www.phinc-group.com\/dose-optimization-in-oncology\/#primaryimage"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/dose-optimization-in-oncology\/#primaryimage"
                    },
                    "thumbnailUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/image-a-la-une-midd-challenge-oncology-optimus-project.png",
                    "datePublished": "2026-06-15T08:48:44+00:00",
                    "dateModified": "2026-06-26T14:56:15+00:00",
                    "breadcrumb": {
                        "@id": "https:\/\/www.phinc-group.com\/dose-optimization-in-oncology\/#breadcrumb"
                    },
                    "inLanguage": "fr-FR",
                    "potentialAction": [
                        {
                            "@type": "ReadAction",
                            "target": [
                                "https:\/\/www.phinc-group.com\/dose-optimization-in-oncology\/"
                            ]
                        }
                    ]
                },
                {
                    "@type": "ImageObject",
                    "inLanguage": "fr-FR",
                    "@id": "https:\/\/www.phinc-group.com\/dose-optimization-in-oncology\/#primaryimage",
                    "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/image-a-la-une-midd-challenge-oncology-optimus-project.png",
                    "contentUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/06\/image-a-la-une-midd-challenge-oncology-optimus-project.png",
                    "width": 1514,
                    "height": 1039
                },
                {
                    "@type": "BreadcrumbList",
                    "@id": "https:\/\/www.phinc-group.com\/dose-optimization-in-oncology\/#breadcrumb",
                    "itemListElement": [
                        {
                            "@type": "ListItem",
                            "position": 1,
                            "name": "Accueil",
                            "item": "https:\/\/www.phinc-group.com\/en\/"
                        },
                        {
                            "@type": "ListItem",
                            "position": 2,
                            "name": "Optimisation\u00a0de la dose\u00a0en\u00a0oncologie\u00a0: un\u00a0d\u00e9fi\u00a0cach\u00e9\u00a0du MIDD \u00e0\u00a0l&rsquo;\u00e8re\u00a0du\u00a0projet\u00a0Optimus"
                        }
                    ]
                },
                {
                    "@type": "WebSite",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#website",
                    "url": "https:\/\/www.phinc-group.com\/fr\/",
                    "name": "PhinC Group",
                    "description": "Quantitative Pharmacology Solutions &amp; Modeling",
                    "publisher": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#organization"
                    },
                    "potentialAction": [
                        {
                            "@type": "SearchAction",
                            "target": {
                                "@type": "EntryPoint",
                                "urlTemplate": "https:\/\/www.phinc-group.com\/fr\/?s={search_term_string}"
                            },
                            "query-input": {
                                "@type": "PropertyValueSpecification",
                                "valueRequired": true,
                                "valueName": "search_term_string"
                            }
                        }
                    ],
                    "inLanguage": "fr-FR"
                },
                {
                    "@type": "Organization",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#organization",
                    "name": "PhinC Group",
                    "url": "https:\/\/www.phinc-group.com\/fr\/",
                    "logo": {
                        "@type": "ImageObject",
                        "inLanguage": "fr-FR",
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/",
                        "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg",
                        "contentUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg",
                        "width": 600,
                        "height": 600,
                        "caption": "PhinC Group"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/"
                    }
                },
                {
                    "@type": "Person",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a",
                    "name": "Mohamed Taourirt",
                    "image": {
                        "@type": "ImageObject",
                        "inLanguage": "fr-FR",
                        "@id": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "url": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "contentUrl": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "caption": "Mohamed Taourirt"
                    },
                    "url": "https:\/\/www.phinc-group.com\/fr\/author\/mtaourirt\/"
                }
            ]
        }
    },
    "_links": {
        "self": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5035",
                "targetHints": {
                    "allow": [
                        "GET"
                    ]
                }
            }
        ],
        "collection": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts"
            }
        ],
        "about": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/types\/post"
            }
        ],
        "author": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/users\/2"
            }
        ],
        "replies": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/comments?post=5035"
            }
        ],
        "version-history": [
            {
                "count": 12,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5035\/revisions"
            }
        ],
        "predecessor-version": [
            {
                "id": 5053,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5035\/revisions\/5053"
            }
        ],
        "wp:featuredmedia": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/media\/5047"
            }
        ],
        "wp:attachment": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/media?parent=5035"
            }
        ],
        "wp:term": [
            {
                "taxonomy": "category",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/categories?post=5035"
            },
            {
                "taxonomy": "post_tag",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/tags?post=5035"
            },
            {
                "taxonomy": "service-associe",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/service-associe?post=5035"
            }
        ],
        "curies": [
            {
                "name": "wp",
                "href": "https:\/\/api.w.org\/{rel}",
                "templated": true
            }
        ]
    }
}